Tempus AI EBIT per osake

Mitä Tempus AI tekee? Tempus AI Inc, listed on the stock market with ticker TEM and ISIN US88023B1035, is a U.S.-based company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Headquartered in Chicago, the company employs approximately 3,800 people. Tempus AI Inc completed its initial public offering (IPO) on June 14, 2024. The company's website is www.tempus.com. Tempus AI Inc provides next-generation diagnostics across multiple disease areas, utilizing data and analytics to support personalized medicine. Its product offerings include genomics, data analytics, and artificial intelligence applications. The genomics division operates laboratories that deliver next-generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and various anatomic and molecular pathology testing services. The AI applications division focuses on developing algorithmic diagnostics, software as a medical device, and clinical decision support tools. The company's primary AI platform, Next, uses machine learning to analyze routinely generated data, aiming to proactively identify and address care gaps for patients in oncology and cardiology. Tempus AI Inc is positioned as a technology company within the life sciences sector, leveraging advanced data capabilities to enhance medical care and treatment personalization. Tempus AI on yksi Eurpooliin suosituimmista yhtiöistä.